Mikhail Blagosklonny is a professor at Roswell Park institute teaching oncology. Beyond being a cancer expert, Blagosklonny is also a leading expert in the emerging science of aging, or more precisely, preventing aging. He received his medical degree and his Ph.D. in experimental medicine and cardiology from First Pavlov State Medical University. Blagosklonny eventually became the senior scientist at Ordway Research Institute in 2009, but he started his professorship as an associate professor of medicine at New York Medical College in 2002. Blagosklonny has researched such transitional topics in aging and oncology as targeted cancer therapy and general traditional cancer therapy as well as anti aging drugs and biogerontology. View Mikhail’s profile on Google Scholar
Rapamycin is already a proven cancer fighting drug. In addition to Mikhail Blagosklonny’s professional endeavors in the medical field itself, he is also a medical editor in chief for two leading medical publications Cell Cycle and Oncotarget. The correlation in oncology which is the treatment and study of cancer and anti aging is in certain cancer drug’s ability to protect healthy cells either from the ravages of cancerous cells or from the treatment utilized to eradicate the cancerous cells. He asserts that TOR signaling, a therapy utilized in cancer treatment and developing successful cancer fighting drugs is also relevant to fighting the effects of aging. Visit ResearchGate.Net to know more about Mikhail’s latest work.